The polygenic basis of relapse after a first episode of schizophrenia

González Segura, Àlex ; Prohens, Llucia ; Gassó, Patricia ; Rodríguez, Natalia ; Garcia-Rizo, Clemente ; Moreno-Izco, Lucía ; Andreu-Bernabeu, Álvaro ; Zorrilla, Iñaki ; Mane, Anna ; Rodríguez-Jiménez, Roberto ; Roldán, Alexandra ; Sarró, Salvador ; Ibáñez, Ángela ; Usall, Judith ; Sáiz, Pilar A ; Cuesta, Manuel J. ; Parellada, Mara ; González-Pinto, Ana ; Berrocoso, Ester ; Bernardo, Miquel ; Mas, Sergi ; Mezquida, Gisela ; Arbelo, Néstor ; De Matteis, Mario ; Galvañ, Joaquín ; Duque Guerra, Alejandra ; Arias i Queralt, Laia ; Perez-Bacigalupe, Maria ; Gonzalez-Ortega, Itxaso ; Toll, Alba ; Casanovas, Francesc ; Sanchez-Pastor, Luis ; Valtueña, Mercedes ; Pomarol-Clotet, Edith ; García-León, Maria Ángeles ; Butjosa, Ana ; Rubio-Abadal, Elena ; Ribeiro, María ; López-Ilundain, Jose M. ; Saiz-Ruiz, Jeronimo ; León-Quismondo, Luis ; Rivero, Olga ; Ruiz, Pedro (Universidad de Zaragoza) ; Echevarría, Rafael Segarra ; García-Portilla, M. Paz

Resumen: Little is known about genetic predisposition to relapse. Previous studies have linked cognitive and psychopathological (mainly schizophrenia and bipolar disorder) polygenic risk scores (PRS) with clinical manifestations of the disease. This study aims to explore the potential role of PRS from major mental disorders and cognition on schizophrenia relapse. 114 patients recruited in the 2EPs Project were included (56 patients who had not experienced relapse after 3 years of enrollment and 58 patients who relapsed during the 3-year follow-up). PRS for schizophrenia (PRS-SZ), bipolar disorder (PRS-BD), education attainment (PRS-EA) and cognitive performance (PRS-CP) were used to assess the genetic risk of schizophrenia relapse.Patients with higher PRS-EA, showed both a lower risk (OR=0.29, 95% CI [0.11–0.73]) and a later onset of relapse (30.96± 1.74 vs. 23.12± 1.14 months, p=0.007. Our study provides evidence that the genetic burden of neurocognitive function is a potentially predictors of relapse that could be incorporated into future risk prediction models. Moreover, appropriate treatments for cognitive symptoms appear to be important for improving the long-term clinical outcome of relapse.

Idioma: Inglés

DOI: 10.1016/j.euroneuro.2023.06.003

Año: 2023

Publicado en: EUROPEAN NEUROPSYCHOPHARMACOLOGY 75 (2023), 80-92
ISSN: 0924-977X

Factor impacto JCR: 6.1 (2023)

Categ. JCR: CLINICAL NEUROLOGY rank: 22 / 280 = 0.079 (2023) - Q1 - T1
Categ. JCR: PSYCHIATRY rank: 21 / 279 = 0.075 (2023) - Q1 - T1
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 26 / 354 = 0.073 (2023) - Q1 - T1
Categ. JCR: NEUROSCIENCES rank: 32 / 310 = 0.103 (2023) - Q1 - T1

Factor impacto CITESCORE: 10.3 - Pharmacology (Q1) - Psychiatry and Mental Health (Q1) - Neurology (Q1) - Pharmacology (medical) (Q1) - Neurology (clinical) (Q1) - Biological Psychiatry (Q1)

Factor impacto SCIMAGO: 1.756 - Biological Psychiatry (Q1) - Neurology (Q1) - Psychiatry and Mental Health (Q1) - Pharmacology (Q1) - Pharmacology (medical) (Q1) - Neurology (clinical) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI08-0208
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI11-00325
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI16-00612

Tipo y forma: Article (Published version)

Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)